BCL11A and Schnyder corneal dystrophy: Exagamglogene autotemcel (exa-cel) (trial: phase I/II; regulatory status: approved by the FDA and UK MHRA for SCD and transfusion-dependent β-thalassemia (2023-2024)): Exa-cel employs CRISPR-Cas9 to disrupt the erythroid enhancer of BCL11A, reactivating HBF production by targeting the HBG1 and HBG2 promoters in autologous hematopoietic stem cells.